Article
Pharmacology & Pharmacy
Jennifer Walsh, Tiziana Masini, Benedikt D. Huttner, Lorenzo Moja, Martina Penazzato, Bernadette Cappello
Summary: Gaps in global availability and use of age-appropriate formulations of medicines for children still exist. To address this issue, the World Health Organization has developed a pQTPP tool to evaluate the age-appropriateness of formulations and identify potential gaps.
Article
Medicine, General & Internal
Lin Bai, Yuqi Zhan, Yue Zhou, Yichen Zhang, Luwen Shi, Sumit Gupta, Avram Denburg, Xiaodong Guan
Summary: This study assessed whether the inclusion of essential anticancer medicines for children in the WHO Essential Medicine for Children list was supported by clinical evidence. The findings showed limited clinical evidence for most anticancer medicine indications in children, suggesting a need for improvement in the criteria for clinical benefit and evidence reporting.
Article
Public, Environmental & Occupational Health
Alessandro Petrella, Filomena Fortinguerra, Agnese Cangini, Andrea Pierantozzi, Francesco Trotta
Summary: This study analyzed the availability and use of essential medicines in Italy based on the WHO Essential Medicines List. It found a high coverage and reimbursement rate for essential medicines in Italy, indicating their importance in healthcare policy choices. The study also highlighted the need for more frequent updates and easier access to information on rejected medicines.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Public, Environmental & Occupational Health
Kristina Jenei, Zeba Aziz, Christopher Booth, Bernadette Cappello, Francesco Ceppi, Elisabeth G. E. de Vries, Antonio Fojo, Bishal Gyawali, Andre Ilbawi, Dorothy Lombe, Manju Sengar, Richard Sullivan, Dario Trapani, Benedikt D. Huttner, Lorenzo Moja
Summary: The selection of cancer medicines for national procurement requires consideration of various factors, and the WHO has implemented updated processes and selection principles to promote the procurement of high-value essential cancer medicines.
LANCET GLOBAL HEALTH
(2022)
Article
Oncology
G. Vassal, O. Kozhaeva, S. Griskjane, F. Arnold, K. Nysom, L. Basset, L. Kameric, A. Kienesberger, S. Kamal, N. Cherny, G. Bricalli, N. Latino, P. Kearns
Summary: Access to essential medicines for children and adolescents with cancer in Europe is lacking, with shortages, financial accessibility, availability of safe age-appropriate oral formulations, and pain management presenting urgent issues that need to be addressed.
ANNALS OF ONCOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Zhe Chen, Siyu Li, Kun Zou, Hailong Li, Linan Zeng, Xiaoxi Lu, Zhi-Jun Jia, Guo Cheng, Lingli Zhang
Summary: The availability of essential anticancer medicines for children in public hospitals in Sichuan Province, China is low, with most generics and original brands having inadequate availability. Generics are generally priced lower than original brands, but some medicines exceed the International Reference Price.
FRONTIERS IN PUBLIC HEALTH
(2022)
Editorial Material
Infectious Diseases
Michael Sharland, Veronica Zanichelli, Loice Achieng Ombajo, Joel Bazira, Bernadette Cappello, Ronald Chitatanga, Pem Chuki, Sumanth Gandra, Haileyesus Getahun, Stephan Harbarth, Mark Loeb, Marc Mendelson, Lorenzo Moja, Celine Pulcini, Hatim Sati, Evelina Tacconelli, Mei Zeng, Benedikt Huttner
Summary: AWaRe is a WHO system that classifies antibiotics based on their spectrum of activity and potential for antibiotic resistance development. The WHO aims for at least 60% of prescribed antibiotics globally to be from the Access category, with narrow spectrum and low potential for resistance, by 2023. The AWaRe Book provides simple guidance for empiric antibiotic prescribing to improve the appropriateness of antibiotic use.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Pharmacology & Pharmacy
Jennifer C. Duncan, Louise E. Bracken, Anthony J. Nunn, Matthew Peak, Mark A. Turner
Summary: A novel tool has been developed and tested to assess the appropriateness of dosage forms for pediatric use and estimate the proportion of formulations considered 'inappropriate' in hospitalized pediatric patients. The tool has shown high inter-rater reliability and can identify medicines that would benefit from improved pediatric formulations.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2022)
Review
Pharmacology & Pharmacy
Xin Ma, Xuxu Yin, Meng Li, Yanwen Wang, Hongxia Xin, Wei Liu
Summary: The study aims to enhance the development of an essential medicines list for the elderly and promote appropriate drug use among older people. Comparison with four potentially inappropriate medication criteria revealed that 26% of essential medicines are included as potentially inappropriate.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Elizabeth F. Peacocke, Sonja L. Myhreid, Hakan Safaralilo Foss, Unni Gopinathan
Summary: The objective of this review was to identify the factors affecting the adaptation and implementation of the World Health Organization Model List of Essential Medicines (WHO EML) at the national level. The study found that the design of institutions, governance, and leadership are crucial for national medicine lists (NMLs) and that investments in processes and institutions are needed to support various stages of the implementation pathway.
Article
Public, Environmental & Occupational Health
Yue Zhou, Huseyin Naci, Dingyi Chen, Lin Bai, Luwen Shi, Xiaodong Guan, Anita Katharina Wagner
Summary: This study examined the overall survival benefits of targeted cancer drugs listed on the WHO Essential Medicines List since 2015 and assessed the consistency of decisions made in 2019 and 2021 with specific criteria. The study found areas where adherence to WHO criteria and communication of approval processes can be improved.
Article
Pharmacology & Pharmacy
Zhe Chen, Siyu Li, Imti Choonara, Linan Zeng, Zhi-jun Jia, Guo Cheng, Qin Yu, Lingli Zhang
Summary: The accessibility of essential medicines for children in public sector in Sichuan Province of China is low, with prices higher than international reference prices. However, most medicines for treating childhood diseases in public sector are affordable, except for a few specific injections.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Nutrition & Dietetics
Woinshet Tizazu, Arnaud Laillou, Bayuh Asmamaw Hailu, Stanley Chitekwe, Kaleab Baye
Summary: Ensuring diet quality in the first 2 years of life is crucial to prevent malnutrition and promote healthy food preferences, but inequalities exist in various dimensions. While there have been modest improvements over the past decade, they are mainly concentrated in limited geographical areas and among wealthier households. Unhealthy practices are increasing and the consumption of nutrient-dense foods is becoming more unequal.
MATERNAL AND CHILD NUTRITION
(2022)
Article
Obstetrics & Gynecology
Joyce Ng'ang'a, Tabeth Chitimbe, Rosemary Mburu, Sara Rushwan, David Ntirushwa, Lester Chinery, A. Metin Guelmezoglu
Summary: Despite WHO recommendations, TXA and HSC are still underused or not used at all for PPH management in many high-burden countries. To ensure access to quality-assured and heat-stable medicines for PPH prevention and treatment in Sub-Saharan African countries, an advocacy initiative was implemented to raise awareness and support the update of PPH guidelines and EMLs.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2022)
Article
Pharmacology & Pharmacy
Amna Saeed, Faria Saeed, Hamid Saeed, Zikria Saleem, Caijun Yang, Jie Chang, Minghuan Jiang, Mingyue Zhao, Muhammad Saqlain, Wenjing Ji, Muhammad Majid Aziz, Krizzia Lambojon, Ali Hassan Gillani, Khezar Hayat, Sabiha Gul, Yu Fang, Zaheer-Ud-Din Babar
Summary: This national survey in Pakistan revealed low availability of cardiovascular disease medicines in both public and private sectors, with high prices that pose a significant burden on the lowest paid government workers. Compared to other low and middle income countries, the affordability of standard cardiovascular drug treatment in Pakistan was found to be low.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Obstetrics & Gynecology
David G. Sweet, Mark Turner, Zbynek Stranak, Richard Plavka, Paul Clarke, Ben Stenson, Dominique Singer, Rangmar Goelz, Laura Fabbri, Guido Varoli, Annalisa Piccinno, Debora Santoro, Dorothea Del Buono, Christian P. Speer
Summary: This study assessed the neurological, respiratory, and general health status of premature infants treated with a new synthetic surfactant enriched with SP-B and SP-C proteins at 24 months corrected age. The results showed that the surfactant treatment was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years of age.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Anne Smits, Pieter Annaert, Giacomo Cavallaro, Pieter A. J. G. De Cock, Saskia N. de Wildt, Jenny M. Kindblom, Florian B. Lagler, Carmen Moreno, Paula Pokorna, Michiel F. Schreuder, Joseph F. Standing, Mark A. Turner, Benedetto Vitiello, Wei Zhao, Annelie-Martina Weingberg, Raffaella Willmann, John van den Anker, Karel Allegaert
Summary: Developmental pharmacology focuses on the impact of maturation on drug metabolism and effects in pediatric patients, providing insights into drug development strategies and highlighting the importance of considering developmental pharmacodynamics. This paper summarizes current knowledge, identifies remaining gaps, and suggests innovative approaches for studying drug disposition and effects in children.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pediatrics
Charalampos Kotidis, David Wertheim, Michael Weindling, Heike Rabe, Mark A. Turner
Summary: Monitoring patent ductus arteriosus (PDA) in premature infants using standard neonatal monitoring, including ECG and blood pressure waveform analysis, may provide potential biomarkers for continuous evaluation of PDA diameter and function. The study found significant correlations between PDA diameter and various parameters derived from ECG and blood pressure waveforms, suggesting a promising approach for assessing PDA status.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Review
Pediatrics
Rian Hayes, Jack Hartnett, Gergana Semova, Cian Murray, Katherine Murphy, Leah Carroll, Helena Plapp, Louise Hession, Jonathan O'Toole, Danielle McCollum, Edna Roche, Elinor Jenkins, David Mockler, Tim Hurley, Matthew McGovern, John Allen, Judith Meehan, Frans B. Plotz, Tobias Strunk, Willem P. de Boode, Richard Polin, James L. Wynn, Marina Degtyareva, Helmut Kuester, Jan Janota, Eric Giannoni, Luregn J. Schlapbach, Fleur M. Keij, Irwin K. M. Reiss, Joseph Bliss, Joyce M. Koenig, Mark A. Turner, Christopher Gale, Eleanor J. Molloy
Summary: Neonatal sepsis, a leading cause of infant mortality, has diverse definitions based on microbiological culture, laboratory tests, and clinical signs. An international consensus-based definition could improve research comparability and clinical outcomes.
PEDIATRIC RESEARCH
(2023)
Review
Pediatrics
Cian J. Henry, Gergana Semova, Ellen Barnes, Isabel Cotter, Tara Devers, Aisyah Rafaee, Andreea Slavescu, Niamh O. Cathain, Danielle McCollum, Edna Roche, David Mockler, John Allen, Judith Meehan, Claus Klingenberg, Jos M. Latour, Agnes van den Hoogen, Tobias Strunk, Eric Giannoni, Luregn J. Schlapbach, Marina Degtyareva, Frans B. Plotz, Willem P. de Boode, Lars Naver, James L. Wynn, Helmut Kuster, Jan Janota, Fleur M. Keij, Irwin K. M. Reiss, Joseph M. Bliss, Richard Polin, Joyce M. Koenig, Mark A. Turner, Christopher Gale, Eleanor J. Molloy
Summary: This article reports a wide variation in outcome reporting among RCTs on the management of neonatal sepsis. The lack of standardized outcome reporting hinders comparison and synthesis of data, making it unlikely for future meta-analyses to provide conclusive recommendations on the management of neonatal sepsis.
PEDIATRIC RESEARCH
(2022)
Review
Medical Informatics
J. Preston, B. Nafria, A. Ohmer, S. Gaillard, P. Dicks, L. West, M. A. Turner
Summary: This paper emphasizes the importance of involving children and families in the design and implementation of pediatric clinical research to improve pediatric healthcare, medicine development, and technological advances. It introduces the International Children's Advisory Network (iCAN) and European Young Person's Advisory Group Network (eYPAGnet) as examples of how children and families have been engaged in pediatric clinical research, providing practical solutions and lessons learned.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
(2022)
Article
Pediatrics
Louise F. Hill, Michelle N. Clements, Mark A. Turner, Daniele Dona, Irja Lutsar, Evelyne Jacqz-Aigrain, Paul T. Heath, Emmanuel Roilides, Louise Rawcliffe, Clara Alonso-Diaz, Eugenio Baraldi, Andrea Dotta, Mari-Liis Ilmoja, Ajit Mahaveer, Tuuli Metsvaht, George Mitsiakos, Vassiliki Papaevangelou, Kosmas Sarafidis, A. Sarah Walker, Michael Sharland
Summary: The study compared the efficacy of an optimized vancomycin regimen with a standard regimen in infants with late onset Gram-positive sepsis. The results showed that the optimized regimen did not demonstrate non-inferiority in terms of efficacy and a potential hearing safety signal was identified. Therefore, this study highlights the importance of robust clinical safety assessments of antibiotic dosing regimens in infants.
LANCET CHILD & ADOLESCENT HEALTH
(2022)
Review
Pharmacology & Pharmacy
Catherine Litalien, Sophie Berube, Catherine Tuleu, Andrea Gilpin, Emilie Kate Landry, Marie Valentin, Robert Strickley, Mark A. Turner
Summary: Developing suitable paediatric formulations and ensuring access to them are crucial for optimal pharmacotherapy for children. While progress has been made in the acceptability of solid oral dosage forms in children, further research is needed. Additionally, access to paediatric formulations is fragmented and unequal, requiring a more globalized registration approach.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Medical Informatics
Morenike Oluwatoyin Folayan, Magda Conway, Carolyn Russo, Nilza Diniz, Lungile P. Jafta, Nadia A. Sam-Agudu, Sarah Bernays, Victor M. Santana, Carla Epps, Mark A. Turner
Summary: The concept of health equity requires equitable access to healthcare, including pediatric drug development. However, many communities are under-represented in pediatric drug development programs. Community engagement and collaboration are recognized as crucial for building a more equitable healthcare system.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
(2022)
Article
Pharmacology & Pharmacy
Jennifer C. Duncan, Louise E. Bracken, Anthony J. Nunn, Matthew Peak, Mark A. Turner
Summary: A novel tool has been developed and tested to assess the appropriateness of dosage forms for pediatric use and estimate the proportion of formulations considered 'inappropriate' in hospitalized pediatric patients. The tool has shown high inter-rater reliability and can identify medicines that would benefit from improved pediatric formulations.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2022)
Article
Pediatrics
Karel Allegaert, Heidrun Hildebrand, Kanwaljit Singh, Mark A. A. Turner
Summary: The International Neonatal Consortium aims to define reference ranges for commonly used laboratory values in neonates, but there is a lack of standardized and complete published information on these values. This hinders treatment comparison, safety monitoring, and clinical management.
PEDIATRIC RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Anna O'Donovan, Jennifer C. Duncan, Kuan-Yin Li, Lucy Del-Nevo, Andrea Gill, Matthew Peak, Mohamed A. Alhnan
Summary: Point-of-care manufacturing such as 3D printing has gained attention in the pharmaceutical industry, but there is limited information on the quantity, dosage form, and reasons for prescribing patient-specific items. This study analyzed prescription data in England from 2012 to 2020 to quantify and examine trends in the prescribing of "Specials," unlicensed medicines formulated for specific prescriptions. The findings showed a significant decrease in spending on Specials due to a reduction in the number of items issued, primarily driven by changes in drug pricing and the availability of licensed alternatives. The study's results provide important insights for formulation scientists in designing personalized medicines at the point of care.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)